文献速递临床试验与 GCP基础与转化研究

四逆汤改善脓毒症免疫功能:一项先导性随机对照试验的研究方案

Si-ni-tang (a Chinese herbal formula) for improving immunofunction in sepsis: study protocol for a pilot randomized controlled trial.
PubMed 文献 · Trials · 2019-08-28

本研究为一项先导性随机对照试验,纳入入住内科重症监护室的脓毒症患者,随机分为对照组与四逆汤组,两组均按拯救脓毒症运动指南接受标准治疗,四逆汤组另接受四逆汤150 mL/日共3天口服或胃管注入,对照组接受150 mL生理盐水。主要结局为评估该治疗可行性,次要结局包括单核细胞人类白细胞抗原-DR表达、降钙素原、CD4+/CD8+ T淋巴细胞比值及28天全因死亡率、SOFA评分、APACHE II评分等临床指标。

要点

  • 四逆汤组在标准治疗基础上加用四逆汤150 mL/日共3天,对照组给予等量生理盐水。
  • 主要结局为评估四逆汤治疗脓毒症的可行性,而非疗效。
  • 次要结局包括免疫功能指标及28天全因死亡率、SOFA与APACHE II评分。

核心结论

  • 本研究旨在评估以四逆汤作为拯救脓毒症运动指南推荐标准治疗的辅助治疗、用于脓毒症疗效评价的可行性。

研究设计与样本

  • 先导性随机对照研究,纳入入住内科重症监护室的合格脓毒症患者,随机分配至对照组或四逆汤组。
  • 两组均按拯救脓毒症运动指南推荐接受标准治疗;四逆汤组另接受四逆汤150 mL/日共3天口服或胃管注入,对照组接受150 mL生理盐水。
  • 主要结局为评估该治疗的可行性;次要结局包括单核细胞人类白细胞抗原-DR表达、降钙素原、CD4+/CD8+ T淋巴细胞比值,以及28天全因死亡率、第0天和第3天的SOFA评分与APACHE II评分。
  • 试验注册于ClinicalTrials.gov,注册号NCT02777606,注册日期2016年6月22日,为回顾性注册。

关键数值与推荐

  • 四逆汤用法为150 mL/日共3天,口服或胃管注入;对照组给予150 mL生理盐水。
  • 疗效评价指标包括单核细胞人类白细胞抗原-DR表达、降钙素原、CD4+/CD8+ T淋巴细胞比值、28天全因死亡率、第0天和第3天SOFA评分与APACHE II评分。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immunologic derangement may be the critical pathophysiologic mechanism in sepsis, and immunotherapy might be a potential new treatment. Si-ni-tang (SNT), an ancient Chinese herbal formula documented in Shanghan Lun, has been used for treating severe sepsis for thousands of years. Research shows that it may have a therapeutic benefit for sepsis. This study will evaluate the feasibility of testing the effects of SNT on immune function in sepsis patients. METHODS/DESIGN: This is a pilot randomized controlled study. Eligible sepsis patients admitted to our medical intensive care unit will be randomly allocated to the control group or the SNT group. Both groups will receive standard therapy according to the recommendations of the Surviving Sepsis Campaign. In addition, the SNT group will receive SNT (150 mL per day for 3 days) orally or by gastric tube, while the control group will receive 150 mL of normal saline. The primary outcome is to assess the feasibility of this treatment. The secondary outcomes include: (1) immune function measured by monocyte human leukocyte antigen-DR (mHLA-DR) expression, procalcitonin, and the ratio of CD4+ to CD8+ T lymphocytes and (2) other clinical data, such as the 28-day all-cause mortality, Sequential Organ Failure Assessment (SOFA) scores, Acute Physiology and Chronic Health Evaluation (APACHE) II scores, both of the latter on days 0 and 3. DISCUSSION: This study aims to evaluate the feasibility of testing the efficacy of SNT for treating sepsis when used as an adjunctive treatment with the standard therapy recommended by the Surviving Sepsis Campaign. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02777606 . Registered on 22 June 2016. Retrospectively registered. https://clinicaltrials.gov/.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Zeng R, Zheng Y, Fan R, et al. Si-ni-tang (a Chinese herbal formula) for improving immunofunction in sepsis: study protocol for a pilot randomized controlled trial. Trials. 2019. PMID: 31462310. doi:10.1186/s13063-019-3646-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。